Dr. Reddy's Reports Q1FY27 Results; Revenues Stand at ₹8,071 Crores Amid Operational Challenges

Dr. Reddy's Reports Q1FY27 Results; Revenues Stand at ₹8,071 Crores Amid Operational Challenges​

Dr. Reddy's Laboratories Limited reported its financial results for the first quarter of FY27, with consolidated revenues reaching ₹8,071 crores (US$853 million). The company posted a decline of 5.6% year-on-year (YoY), while sequentially it recorded a growth of 7.4%.

The financial performance reflected the impact of lower lenalidomide sales and the provision of ₹240 crores for inventory and related costs associated with recent semaglutide API challenges. Despite these headwinds, the underlying base business continued to demonstrate strong double-digit growth across key geographies, supported by new product launches and favorable currency movements.

Key Financial Performance Highlights​

The company reported a consolidated gross profit margin of 46.5%, which marked a decrease of 1,039 basis points (bps) YoY but an increase of 169 bps sequentially. The decline in margins was attributed to lower lenalidomide sales, the aforementioned semaglutide API provision, and elevated solvent costs linked to the Middle East conflict.

Excluding the semaglutide API related provision, the overall gross margin stood at 49.4%, with Global Generics reporting a margin of 53.8% and PSAI maintaining 12.9%.

The SG&A spend was ₹2,882 crores, representing an increase of 12% YoY and 4% sequentially, accounting for 36% of revenues. This increase was primarily driven by annual personnel increments, adverse forex movements, targeted investments in branded businesses, and elevated freight costs resulting from disruptions related to the Middle East crisis.

R&D expenditure stood at ₹577 crores, which declined 8% YoY but increased 6% sequentially. This spending accounted for 7.1% of revenues and reflected a lower biosimilars development outlay compared to the previous year.

The underlying EBITDA, including other income, was reported at ₹1,009 crores (US$107 million), representing a margin of 12.5%. Excluding the semaglutide API provision, the underlying margin stood at 15.4%. Profit before tax (PBT) reached ₹553 crores (US$58 million), yielding a margin of 6.8%.

Segmental and Operational Snapshot​

The company's performance varied across different business segments:


The management noted that almost 52% of total revenues are derived from branded franchises covering India, Emerging Markets, and the consumer health business in Nicotine Replacement Therapy (NRT).

Strategic Developments and Focus Areas​

Semaglutide and Innovation:
Dr. Reddy's is one of the first companies to secure approval and launch semaglutide for Type-2 diabetes. The company also secured Thai FDA approval for zoliflodacin, a first-in-class treatment for uncomplicated gonorrhoea, making Thailand the first LMIC country to approve the product after US FDA approval.

Regarding the supply interruption of semaglutide, management stated that 180,000 pens were sold before the stoppage. The company is working towards resolving the issue and plans to resume commercial supplies in late September, targeting a market of 6 to 7 million pens between November and March.

Abatacept and Biosimilars:
The USFDA completed a Pre-License Inspection at the biologics manufacturing facility in Bachupally, Hyderabad in June 2026 and issued a Form 483 with seven observations. Management indicated that the observations are addressable, and the company is optimistic about achieving approval for abatacept, which is currently targeted for December.

Financial Health Metrics:
As of June 30, 2026, the operating working capital stood at ₹14,353 crores (US$1.52 billion), a decrease of ₹81 crores from March 31, 2026. The company reported a net cash surplus of ₹3,057 crores (US$323 million). For the full year, management projected CAPEX to be around ₹1,800 crores.

Management Commentary on Market Risks and Growth​

During the earnings call, executives addressed several market concerns:

• Pricing and Competition in Canada: The company stated that for its semaglutide product in Canada, the price is CAD 78. Pricing and reimbursement depend on whether it is a private or public market purchase. Management confirmed there are no anticipated additional pricing beyond what is already set with retailers.
• US Generic Growth: Despite facing significant price erosion in certain years, management reiterated that the US generic segment is at best single-digit growth, compensated by new product launches which provide leveraged growth to emerging and European markets.
• Business Development: The company confirmed it is engaged in business development across various sectors including generics, innovation, biosimilars, and other areas, with the balance sheet being utilized for inorganic opportunities.

The CEO also noted that the commitment to double-digit base business growth remains strong, driven by efforts to build future engines in peptides, biosimilars, consumer health, and innovation.

DRREDDY Stock Price Movement​

On Tuesday, Dr. Reddy's Laboratories Limited shares slipped by 1.46%, settling at ₹1134 as the equity closed lower from its previous close. The stock saw a total traded volume of 2.16 million shares during the session.